日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer

非小细胞肺癌获得性免疫治疗耐药的临床和分子特征

Danish Memon ,Adam J Schoenfeld ,Darwin Ye ,George Fromm ,Hira Rizvi ,Xiang Zhang ,Mohamed Reda Keddar ,Divij Mathew ,Kyung Jin Yoo ,Jingya Qiu ,Jayon Lihm ,Jayalaksmi Miriyala ,Jennifer L Sauter ,Jia Luo ,Andrew Chow ,Umesh K Bhanot ,Caroline McCarthy ,Chad M Vanderbilt ,Cailian Liu ,Mohsen Abu-Akeel ,Andrew J Plodkowski ,Nicholas McGranahan ,Marta Łuksza ,Benjamin D Greenbaum ,Taha Merghoub ,Ikbel Achour ,J Carl Barrett ,Ross Stewart ,Pedro Beltrao ,Taylor H Schreiber ,Andy J Minn ,Martin L Miller ,Matthew D Hellmann

Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification

MDM2 和 MEK 抑制剂联合治疗对同时存在致癌驱动因素和 MDM2 扩增的肺腺癌患者模型有效

Arielle Elkrief, Igor Odintsov, Vladimir Markov, Rebecca Caeser, Pawel Sobczuk, Sam E Tischfield, Umesh Bhanot, Chad M Vanderbilt, Emily H Cheng, Alexander Drilon, Gregory J Riely, William W Lockwood, Elisa de Stanchina, Vijaya G Tirunagaru, Robert C Doebele, Álvaro Quintanal-Villalonga, Charles M R